Biogen has discontinued development of BIIB054

[Farooqji]

fiercebiotech.com/biotech/b...

[Parkinsonjisung]

Is this time to move away from alpha-synuclein clearing therapies? Parkinson seems to be following the ALZ path

[park_bear in reply to Parkinsonjisung]

In this case it may be the failure of an anti-alpha synuclein monoclonal antibody to prevent the accumulation of malformed alpha synuclein, rather than a failure of the alpha synuclein hypothesis itself.

[sharoncrayn in reply to park_bear]

I agree.

[redhawk1 in reply to Parkinsonjisung]

I think Biogen must see more promise with the synergy and knowledge acquired in their recent partnership with Denali Therapeutics.

[redhawk1 in reply to redhawk1]

. . . and i am in the Roche Prothena study. So, i wonder how the Biogen decision will affect Roche going forward. Of course, Roche just purchased Inflazome for their know how. I wonder if they may see some kind of synergy between their monoclonal antibody drug and the Inflazome drug now in trial . . . mmmmm